Open AccessJournal Article
The spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria: A multicenter study (PL01.003)
Andrew J. Solomon,Dennis Bourdette,Anne H. Cross,Angela Applebee,Philip Skidd,Diantha B. Howard,Rebecca Spain,Michelle Cameron,Edward Kim,Michele Mass,Vijayshree Yadav,Ruth H. Whitham,Erin E. Longbrake,Robert T. Naismith,Gregory F. Wu,Becky J. Parks,Dean M. Wingerchuk,Brian L. Rabin,Michel Toledano,W. O. Tobin,Orhun H. Kantarci,Jonathan Carter,B. M. Keegan,Brian G. Weinshenker +23 more
Reads0
Chats0
TLDR
Misdiagnosis of MS is a common problem that may lead to treatment-related as well as psychosocial morbidity and misinterpretation and misapplication of MS clinical and radiographic diagnostic criteria are important causes of misdiagnosis.Abstract:
Objective : To characterize patients misdiagnosed with multiple sclerosis (MS) and hypothesize common causes for misdiagnosis.
Background : Misdiagnosis of MS is a persistent if not growing problem despite, and perhaps because of, improved radiographic diagnostic techniques. Few studies have characterized the contemporary spectrum of MS misdiagnosis.
Methods : Over 13 months, neurologists at four academic MS Centers submitted data concerning individual patients whom they had evaluated and determined to have been misdiagnosed with MS.
Results : Of 110 misdiagnosed patients, 51 (46[percnt]) had “definite” and 59 (54[percnt]) “probable” misdiagnoses according to study definitions. The most frequent primary diagnoses were migraine alone or in combination with other diagnoses 24 (21[percnt]), fibromyalgia 16 (15[percnt]), nonspecific or non-localizing neurological symptoms with abnormal MRI 13 (12[percnt]), and conversion or psychogenic disorder 12 (11[percnt]). 27 additional diagnoses were reported. 32 (29[percnt]) of patients carried a misdiagnosis between 3-9 years and 29 (26[percnt]) for 10-20 years. 77 (70[percnt]) had taken disease modifying therapy, including natalizumab 14 (13[percnt]), mitoxantrone 2 (2[percnt]), cyclophosphamide 1 (1[percnt]). Four (4[percnt]) had participated in a research study of an MS therapy. In 79 (72[percnt]) of patients, participating neurologists indicated that there was evidence an earlier missed opportunity to make a correct diagnosis and 34 (31[percnt]) suffered unnecessary morbidity as a direct result of a misdiagnosis. Inappropriate attribution of symptoms to demyelinating disease contributed to misdiagnosis in 72 (65[percnt]) patients, and reliance upon historical symptoms without corroborating objective evidence of a lesion in 53 (48[percnt]). Over-reliance on MRI abnormalities to satisfy dissemination in space in a patient with nonspecific neurological symptoms contributed to misdiagnosis in 66 (60[percnt]).
Conclusions : Misdiagnosis of MS is a common problem that may lead to treatment-related as well as psychosocial morbidity. Misinterpretation and misapplication of MS clinical and radiographic diagnostic criteria are important causes of misdiagnosis. Disclosure: Dr. Solomon has received personal compensation from Haymarket Media as a speaker. Dr. Bourdette has received personal compensation for activities with Biogen Idec, Serono, and Teva Neurosciences as a speaker/faculty. Dr. Cross has received personal compensation for activities with Biogen Idec, Genzyme Corporation, GlaxoSmithKline, Inc., Hoffman-La Roche, Teva Neuroscience, Novartis, and Questcor. Dr. Applebee has nothing to disclose. Dr. Skidd has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Spain has nothing to disclose. Dr. Michelle Cameron has received compensation for activities with Acorda therapeutics, MD consult and ReWalk as a consultant. Dr. Kim has received personal compensation for activities with Teva pharmaceutical and Genzyme. Dr. Mass has nothing to disclose. Dr. Yadav has received personal compensation for activities with Novartis as a consultant. Dr. Yadav has received research support from Biogen Idec. Dr. Whitham has received personal compensation for activities with Chugai Pharmaceutical as a data safety monitoring board member. Dr. Longbrake has received personal compensation for activities with Genzyme. Dr. Naismith received personal compensation for activities with Alkermes, Acorda, Bayer, Biogen Idec, Genentech Inc., Genzyme Corporation, EMD Serono, Novartis, and Questcor as a consultant and from Acorda Therapeutics and Genzyme Corporation as a speaker Dr. Wu has received personal compensation for activities with Biogen Idec and Pfizer Inc. Dr. Parks has received personal compensation for activities with BiogenIdec and Novartis as an advisory board member. Dr. Wingerchuk has received personal compensation for serving on a clinical trial adjudication committee for Medimmune. Dr. Wingerchuk has received personal compensation in an editorial capacity for The Neurologist. Dr. Wingerchuk has received research su Dr. Rabin has nothing to disclose. Dr. Toledano has nothing to disclose. Dr. Tobin has nothing to disclose. Dr. Kantarci has nothing to disclose. Dr. Carter has received personal compensation for activities with EMD-Serono, University of Louisville and Omnicare, Inc. for serving as a member of the board and various other activities. Dr. Carter has received research support from the Sanofi, Genzyme Dr. Keegan has received research support from Terumo BCT. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, Mitsubishi Pharmaceuticals, MedImmune Pharmaceuticals, Chugai, and Chord as a consultant. Dr. Weinshenker has received royalty payments from RSR Ltd. and Oxfordread more
Citations
More filters
Journal ArticleDOI
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German–Austrian retrospective multicenter study in patients with a clinically isolated syndrome
André Huss,Steffen Halbgebauer,Patrick Öckl,Corinna Trebst,Annette Spreer,Nadja Borisow,Andrea Harrer,Isabel Brecht,Bettina Balint,Oliver Stich,Sabine Schlegel,Nele Retzlaff,Alexander Winkelmann,Romy Roesler,Florian Lauda,Özlem Yildiz,Elke Voß,Rainer Muche,Sebastian Rauer,Florian Then Bergh,Markus Otto,Friedemann Paul,Brigitte Wildemann,Jörg Kraus,Klemens Ruprecht,Martin Stangel,Mathias Buttmann,Uwe K. Zettl,Hayrettin Tumani +28 more
TL;DR: It is confirmed that in patients with CIS the risk of conversion to MS substantially increases if OCBs are present at onset, and CSF analysis definitely helps to evaluate the prognosis in patients who do not have MS according to the revised McDonald criteria.
Journal ArticleDOI
An In Vitro Diagnostic for Multiple Sclerosis Based on C-peptide Binding to Erythrocytes.
TL;DR: Exogenous C-peptide binding to erythrocytes has potential value in distinguishing MS subjects from non-MS neurologic diseases and healthy controls and a receiver-operator characteristic (ROC) curve generated from the ratio of the sensitivity to 1-selectivity resulted in an area under the curve of 0.97.
Journal ArticleDOI
Malingering vereist verdieping onderzoek en opleiding
TL;DR: In this paper, a verwijdering uit het register van een jaar, met een proeftijd van meerdere jaren, is presented.
Related Papers (5)
Prevalence of Sleep Disturbances, Fatigue, Anxiety and Depression in Multiple Sclerosis (MS) (P1.128)
Sven Rupprecht,Steffen W. Kluckow,Maryam Yahiaoui-Doktor,Orhan Aktas,Andrew T. Chan,Alexander Dressel,Juergen Faiss,Klaus Gehring,Frank Hoffmann,Ulf Kallweit,Wolfgang Koehler,Andreas Kowalik,Michael Lang,Chrstoph Lassek,Sabine Lobenstein,Wilfried Lüer,Mike Matzke,Geert Mayer,Joachim Piatkowski,Udo Polzer,Sebastian Schimrigk,Barbara Schwandt,Carsten Sievers,Konstanze Tinschert,Klaus Uwe Zettl,Sylvia Kotterba,Matthias Schwab +26 more
Comparison of MRI Dissemination in Space Criteria for Predicting a First Clinical Event in Children with the Radiologically Isolated Syndrome (S2.001)
Naila Makhani,Christine Lebrun,Aksel Siva,Sona Narula,Sona Narula,Evangeline Wassmer,J. Nicholas Brenton,Clarissa Carra Dalliere,Jérôme De Seze,Francoise Durand Dubief,Megan Langille,Megan Langille,Rinze F. Neuteboom,Jean Pelletier,Daniela Pohl,Daniela Pohl,Juan Ignacio Rojas,Eugene D. Shapiro,Robert Thompson Stone,Silvia Tenembaum,Mar Tintoré,Ugur Uygunoglu,Wendy Vargas,Orhun H. Kantarci,Darin T. Okuda,Daniel Pelletier,Observatoire Francophone de la Sclérose en Plaques,Société Francophone de la Sclérose en Plaques +27 more
Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients
Daniel Whittam,Alvaro Cobo-Calvo,Alfonso Sebastian Lopez-Chiriboga,Santiago Pardo,James Dodd,Alexander U. Brandt,Klaus Berek,Thomas Berger,Grace Y. Gombolay,Luana Micheli Oliveira,Dagoberto Callegaro,Kimihiko Kaneko,Tatsuro Misu,Bruno Brochet,Bertrand Audoin,Guillaume Mathey,David Laplaud,Eric Thouvenot,Mikael Cohen,Ayman Tourbah,Elisabeth Maillart,Jonathan Ciron,Romain Deschamps,Damien Biotti,Marcelo Matiello,Jacqueline Palace,Ming K. Lim,Kazuo Fujihara,Ichiro Nakashima,Jeffrey Bennett,Lekha Pandit,Tanuja Chitnis,Brian G. Weinshenker,Brigitte Wildemann,Douglas Kazutoshi Sato,Douglas Kazutoshi Sato,Su-Hyun Kim,Ho Jin Kim,Markus Reindl,Michael J. Levy,Sven Jarius,Silvia Tenembaum,Friedemann Paul,Sean J. Pittock,Romain Marignier,Anu Jacob,Anu Jacob +46 more